# Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations

> **NCT01520051** · PHASE3 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 48 (estimated)

## Conditions studied

- Asthma
- Viral Infection

## Interventions

- **DRUG:** Mepolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01520051
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2012-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520051, "Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01520051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*